{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:02:34Z","timestamp":1794070954090,"version":"4.8.0"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1038\/s41395-018-0179-4","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T05:48:29Z","timestamp":1531201709000},"page":"1600-1612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Current Management of Hepatic Encephalopathy"],"prefix":"10.14309","volume":"113","author":[{"given":"Chathur","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmohan S.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210302","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis.","volume":"30","author":"Bustamante","year":"1999","journal-title":"J Hepatol"},{"key":"R2-15-20210302","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis.","volume":"31","author":"DAmico","year":"1986","journal-title":"Dig Dis Sci"},{"key":"R3-15-20210302","first-page":"42","article-title":"Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group.","volume":"23","author":"Coltorti","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"R4-15-20210302","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"key":"R5-15-20210302","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2011.04590.x","article-title":"Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.","volume":"33","author":"Bajaj","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-15-20210302","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/lt.25032","article-title":"Assessment of the spectrum of hepatic encephalopathy: a Multi-Center Study.","volume":"24","author":"Reuter","year":"2018","journal-title":"Liver Transpl"},{"key":"R7-15-20210302","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00018-005-5089-0","article-title":"The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation.","volume":"62","author":"Shawcross","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"R8-15-20210302","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/ajg.2011.157","article-title":"The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers.","volume":"106","author":"Bajaj","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R9-15-20210302","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.","volume":"45","author":"Prasad","year":"2007","journal-title":"Hepatology"},{"key":"R10-15-20210302","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3748\/wjg.14.3609","article-title":"Minimal hepatic encephalopathy matters in daily life.","volume":"14","author":"Bajaj","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R11-15-20210302","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.23128","article-title":"Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test.","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"key":"R12-15-20210302","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1440-1746.2001.02487.x","article-title":"Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.","volume":"16","author":"Das","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-15-20210302","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1111\/j.1572-0241.2001.04130.x","article-title":"Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.","volume":"96","author":"Romero-Gomez","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R14-15-20210302","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.26370","article-title":"The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus.","volume":"58","author":"Amodio","year":"2013","journal-title":"Hepatology"},{"key":"R15-15-20210302","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-012-9365-z","article-title":"Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.","volume":"28","author":"Merli","year":"2013","journal-title":"Metab Brain Dis"},{"key":"R16-15-20210302","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/hepr.12873","article-title":"Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis.","volume":"47","author":"Hanai","year":"2017","journal-title":"Hepatol Res"},{"key":"R17-15-20210302","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/hep.22367","article-title":"Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.","volume":"48","author":"Plank","year":"2008","journal-title":"Hepatology"},{"key":"R18-15-20210302","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00535-017-1370-x","article-title":"Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.","volume":"53","author":"Kitajima","year":"2017","journal-title":"J Gastroenterol"},{"key":"R19-15-20210302","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/MEG.0000000000000986","article-title":"Efficacy of branched-chain amino acid supplementation and walking exercise for preventing sarcopenia in patients with liver cirrhosis.","volume":"29","author":"Hiraoka","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R20-15-20210302","first-page":"CD001939","article-title":"Branched-chain amino acids for people with hepatic encephalopathy.","volume":"5","author":"Gluud","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R21-15-20210302","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00004836-199008000-00016","article-title":"Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.","volume":"12","author":"Riggio","year":"1990","journal-title":"J Clin Gastroenterol"},{"key":"R22-15-20210302","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11011-012-9303-0","article-title":"A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy.","volume":"27","author":"Bajaj","year":"2012","journal-title":"Metab Brain Dis"},{"key":"R23-15-20210302","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hep.1840070404","article-title":"Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial.","volume":"7","author":"Uribe","year":"1987","journal-title":"Hepatology"},{"key":"R24-15-20210302","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/hep.1840070617","article-title":"Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.","volume":"7","author":"Morgan","year":"1987","journal-title":"Hepatology"},{"key":"R25-15-20210302","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/jgh.13666","article-title":"A Randomized Controlled Trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.","volume":"32","author":"Sharma","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R26-15-20210302","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/hep.510260606","article-title":"Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.","volume":"26","author":"Watanabe","year":"1997","journal-title":"Hepatology"},{"key":"R27-15-20210302","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2036.1997.118289000.x","article-title":"Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.","volume":"11","author":"Horsmans","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-15-20210302","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1023\/A:1005556826152","article-title":"Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.","volume":"45","author":"Dhiman","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"R29-15-20210302","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-15-20210302","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","article-title":"Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.","volume":"13","author":"Bucci","year":"1993","journal-title":"Curr Med Res Opin"},{"key":"R31-15-20210302","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.","volume":"38","author":"Mas","year":"2003","journal-title":"J Hepatol"},{"key":"R32-15-20210302","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R33-15-20210302","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/hep.27952","article-title":"Reply.","volume":"63","author":"Bajaj","year":"2016","journal-title":"Hepatology"},{"key":"R35-15-20210302","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","article-title":"Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).","volume":"106","author":"Sidhu","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R36-15-20210302","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","article-title":"Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.","volume":"140","author":"Bajaj","year":"2011","journal-title":"Gastroenterology"},{"key":"R37-15-20210302","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.","volume":"72","author":"Conn","year":"1977","journal-title":"Gastroenterology"},{"key":"R38-15-20210302","first-page":"542","article-title":"Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.","volume":"39","author":"Strauss","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"R39-15-20210302","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.31.6.702","article-title":"Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy.","volume":"31","author":"Tarao","year":"1990","journal-title":"Gut"},{"key":"R40-15-20210302","first-page":"14","article-title":"Treatment of hepatic encephalopathy with non-absorbable antibiotics.","volume":"24","author":"Festi","year":"1992","journal-title":"Ital J Gastroenterol"},{"key":"R41-15-20210302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.23.1.1","article-title":"Treatment of hepatic encephalopathy with metronidazole.","volume":"23","author":"Morgan","year":"1982","journal-title":"Gut"},{"key":"R42-15-20210302","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jamainternmed.2014.4746","article-title":"Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.","volume":"174","author":"Rahimi","year":"2014","journal-title":"JAMA Intern Med"},{"key":"R43-15-20210302","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-15-20210302","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.","volume":"107","author":"Agrawal","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R45-15-20210302","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.","volume":"39","author":"Bajaj","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R46-15-20210302","first-page":"CD008716","article-title":"Probiotics for people with hepatic encephalopathy.","volume":"2","author":"Dalal","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R47-15-20210302","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"R48-15-20210302","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MEG.0b013e32834696f5","article-title":"A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy.","volume":"23","author":"Mittal","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R49-15-20210302","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/hepr.12429","article-title":"Effect of probiotic VSL3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial.","volume":"45","author":"Pratap Mouli","year":"2015","journal-title":"Hepatol Res"},{"key":"R50-15-20210302","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/MEG.0b013e3282f3e6f5","article-title":"An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.","volume":"20","author":"Sharma","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R51-15-20210302","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.","volume":"25","author":"Kircheis","year":"1997","journal-title":"Hepatology"},{"key":"R52-15-20210302","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jceh.2017.01.009","article-title":"The brain-muscle axis in minimal hepatic encephalopathy (MHE): a placebo-controlled, longitudinal double-blind trial With l-Ornithine l-Aspartate (LOLA) - preliminary results.","volume":"7","author":"Pasha","year":"2017","journal-title":"J Clin Exp Hepatol"},{"key":"R53-15-20210302","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1665-2681(19)31989-1","article-title":"Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.","volume":"5","author":"Poo","year":"2006","journal-title":"Ann Hepatol"},{"key":"R54-15-20210302","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0168-8278(98)80237-7","article-title":"Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.","volume":"28","author":"Stauch","year":"1998","journal-title":"J Hepatol"},{"key":"R56-15-20210302","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/hepr.12235","article-title":"Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.","volume":"44","author":"Alvares-da-Silva","year":"2014","journal-title":"Hepatol Res"},{"key":"R57-15-20210302","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/1319-3767.136975","article-title":"Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial.","volume":"20","author":"Sharma","year":"2014","journal-title":"Saudi J Gastroenterol"},{"key":"R58-15-20210302","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"key":"R59-15-20210302","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bcp.2012.10.015","article-title":"Interorgan metabolism of ornithine phenylacetate (OP)-a novel strategy for treatment of hyperammonemia.","volume":"85","author":"Dadsetan","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"R60-15-20210302","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/0148607185009006671","article-title":"Enriched branched-chain amino acid formula versus a casein-based supplement in the treatment of cirrhosis.","volume":"9","author":"Christie","year":"1985","journal-title":"JPEN J Parenter Enter Nutr"},{"key":"R61-15-20210302","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/hep.1840030402","article-title":"Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study.","volume":"3","author":"Wahren","year":"1983","journal-title":"Hepatology"},{"key":"R62-15-20210302","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.1840160123","article-title":"Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial.","volume":"16","author":"Sushma","year":"1992","journal-title":"Hepatology"},{"key":"R63-15-20210302","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1590-8658(00)80027-4","article-title":"Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study.","volume":"32","author":"Laccetti","year":"2000","journal-title":"Dig Liver Dis"},{"key":"R64-15-20210302","first-page":"CD002798","article-title":"Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.","volume":"8","author":"Goh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R65-15-20210302","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/hep.21734","article-title":"Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts.","volume":"46","author":"Cauli","year":"2007","journal-title":"Hepatology"},{"key":"R66-15-20210302","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/jhep.2001.26383","article-title":"Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portacaval anastomosis.","volume":"34","author":"Chung","year":"2001","journal-title":"Hepatology"},{"key":"R67-15-20210302","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.510270535","article-title":"Determinants of outcome of compensated hepatitis C virus-related cirrhosis.","volume":"27","author":"Serfaty","year":"1998","journal-title":"Hepatology"},{"key":"R68-15-20210302","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/MCG.0b013e3182284e13","article-title":"Long-term clinical course of decompensated alcoholic cirrhosis: a prospective study of 165 patients.","volume":"45","author":"Alvarez","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"R69-15-20210302","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","article-title":"Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.","volume":"341","author":"Sort","year":"1999","journal-title":"N Engl J Med"},{"key":"R70-15-20210302","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.jhep.2013.07.020","article-title":"Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.","volume":"59","author":"Simon-Talero","year":"2013","journal-title":"J Hepatol"},{"key":"R71-15-20210302","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1002\/hep.21930","article-title":"Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.","volume":"46","author":"Hassanein","year":"2007","journal-title":"Hepatology"},{"key":"R72-15-20210302","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000171495","article-title":"Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City.","volume":"13","author":"Poo","year":"1995","journal-title":"Dig Dis"},{"key":"R73-15-20210302","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(84)92567-4","article-title":"Oral zinc supplementation improves hepatic encephalopathy. results of a randomised controlled trial.","volume":"2","author":"Reding","year":"1984","journal-title":"Lancet"},{"key":"R74-15-20210302","first-page":"414","article-title":"Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment.","volume":"2","author":"Bresci","year":"1993","journal-title":"Eur J Med"},{"key":"R75-15-20210302","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1475-2891-12-74","article-title":"A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy.","volume":"12","author":"Chavez-Tapia","year":"2013","journal-title":"Nutr J"},{"key":"R76-15-20210302","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/1756283X16645049","article-title":"The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial.","volume":"9","author":"Mousa","year":"2016","journal-title":"Ther Adv Gastroenterol"},{"key":"R77-15-20210302","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.3748\/wjg.v11.i45.7197","article-title":"Effects of L-carnitine in patients with hepatic encephalopathy.","volume":"11","author":"Malaguarnera","year":"2005","journal-title":"World J Gastroenterol"},{"key":"R78-15-20210302","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11011-011-9260-z","article-title":"Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial.","volume":"26","author":"Malaguarnera","year":"2011","journal-title":"Metab Brain Dis"},{"key":"R79-15-20210302","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3945\/ajcn.110.007393","article-title":"Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.","volume":"93","author":"Malaguarnera","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"R80-15-20210302","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s10620-008-0238-6","article-title":"Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.","volume":"53","author":"Malaguarnera","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R82-15-20210302","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy.","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"key":"R83-15-20210302","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R85-15-20210302","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/hep.22853","article-title":"Management of adult patients with ascites due to cirrhosis: an update.","volume":"49","author":"Runyon","year":"2009","journal-title":"Hepatology"},{"key":"R86-15-20210302","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/apt.14361","article-title":"Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.","volume":"46","author":"Goel","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R87-15-20210302","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.cgh.2013.12.020","article-title":"Diagnosis of covert hepatic encephalopathy without specialized tests.","volume":"12","author":"Nabi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R88-15-20210302","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/MEG.0b013e32834d1938","article-title":"Clinical efficacy and safety of lactulose for minimal hepatic encephalopathy: a meta-analysis.","volume":"23","author":"Luo","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R92-15-20210302","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1111\/hepr.12085","article-title":"Physical inactivity and insufficient dietary intake are associated with the frequency of sarcopenia in patients with compensated viral liver cirrhosis.","volume":"43","author":"Hayashi","year":"2013","journal-title":"Hepatol Res"},{"key":"R93-15-20210302","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/ctg.2016.38","article-title":"Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial.","volume":"7","author":"Macias-Rodriguez","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R94-15-20210302","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/lt.24498","article-title":"Liver transplantation significantly improves global functioning and cerebral processing.","volume":"22","author":"Ahluwalia","year":"2016","journal-title":"Liver Transpl"},{"key":"R95-15-20210302","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/lt.22197","article-title":"Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume.","volume":"17","author":"Garcia-Martinez","year":"2011","journal-title":"Liver Transpl"},{"key":"R96-15-20210302","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/TP.0000000000001991","article-title":"Brain integrity changes underlying cognitive and functional recovery postliver transplant continue to evolve over 1 year.","volume":"102","author":"Ahluwalia","year":"2017","journal-title":"Transplantation"},{"key":"R97-15-20210302","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/lt.24864","article-title":"Overt hepatic encephalopathy impairs learning on the EncephalApp stroop which is reversible after liver transplantation.","volume":"23","author":"Acharya","year":"2017","journal-title":"Liver Transpl"},{"key":"R98-15-20210302","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.24517","article-title":"Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts.","volume":"22","author":"Lucidi","year":"2016","journal-title":"Liver Transpl"},{"key":"R99-15-20210302","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cgh.2016.10.028","article-title":"Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement.","volume":"15","author":"Nardelli","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R100-15-20210302","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/ajg.2016.29","article-title":"Cognitive impairment predicts the occurrence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.","volume":"111","author":"Nardelli","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R101-15-20210302","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/jcm3020359","article-title":"Hyponatremia: a risk factor for early overt encephalopathy after transjugular intrahepatic portosystemic shunt creation.","volume":"3","author":"Merola","year":"2014","journal-title":"J Clin Med"},{"key":"R102-15-20210302","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.","volume":"42","author":"Riggio","year":"2005","journal-title":"J Hepatol"},{"key":"R104-15-20210302","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1051-0443(95)71212-X","article-title":"Successful reversal of hepatic encephalopathy with intentional occlusion of transjugular intrahepatic portosystemic shunts.","volume":"6","author":"Kerlan","year":"1995","journal-title":"J Vasc Interv Radiol"},{"key":"R105-15-20210302","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1440-1746.2006.04697.x","article-title":"Portosystemic pressure gradient during transjugular intrahepatic portosystemic shunt with Viatorr stent graft: what is the critical low threshold to avoid medically uncontrolled low pressure gradient related complications?","volume":"23","author":"Chung","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R106-15-20210302","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1002\/hep.20905","article-title":"High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study.","volume":"42","author":"Riggio","year":"2005","journal-title":"Hepatology"},{"key":"R107-15-20210302","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/hep.26314","article-title":"Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.","volume":"57","author":"Laleman","year":"2013","journal-title":"Hepatology"},{"key":"R108-15-20210302","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-0037-1618602","article-title":"Coil-assisted retrograde transvenous obliteration: a valid treatment for gastric variceal hemorrhage and hepatic encephalopathy.","volume":"01","author":"Marsala","year":"2017","journal-title":"Dig Dis Interv"},{"key":"R111-15-20210302","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/hep.28121","article-title":"Fecal microbiota transplantation in the management of hepatic encephalopathy.","volume":"63","author":"Kao","year":"2016","journal-title":"Hepatology"},{"key":"R112-15-20210302","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial.","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"RU113-15-20210302","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/ajg.2011.9","article-title":"Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.","volume":"106","author":"Les","year":"2011","journal-title":"Am J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0179-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/00000434-201811000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:25Z","timestamp":1786542385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201811000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0179-4","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}